Replies to post #99676 on Biotech Values

[DewDiligence]

Do you still think that the launch of an AG warrants a 40% discount to valuation?

As mentioned about halfway down in #msg-42166244, the 40% figure is meant to be the factor applied to the best-case valuation to arrive at the worst-case valuation when there is an AG and no other generic in the market. In all likelihood, an actual AG scenario will be somewhat better. Regards, Dew